CE-marking and commercial launch of Semi-Quantitative COVID-19 IgG Antibody Rapid Test

Abingdon Health plc, a leading international developer and manufacturer of high quality and effective rapid tests, announces the commercial launch and UKCA and CE-marking of AbC-19™ Semi-Q Rapid Test.
By: Abingdon Health plc
 
YORK, U.K. - Dec. 16, 2021 - PRLog -- Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces the commercial launch and UKCA and CE-marking of AbC-19™ Semi-Q Rapid Test, a lateral flow test that detects the presence of IgG neutralising antibodies to the full trimeric spike protein of the SARS-CoV-2 virus and produces semi-quantitative results via a line intensity scorecard. The product was initially launched for research purposes in September 2021.

AbC-19™ Semi-Q Rapid Test is available for use by professionals or trained lay-users, meaning government agencies, pharmacists, testing centres or workplaces can use the test to identify and monitor a person's level of antibody-based protection to COVID-19.

The presence and strength of IgG neutralising antibodies following infection and/or vaccination is a key indicator of an individual's protective immune response to COVID-19. The intensity of the line on the scorecard, which can be seen visually, is proportional to the number of IgG antibodies present in the finger-prick blood sample, with higher levels of antibodies producing a stronger test line.

Full press release: https://www.abingdonhealth.com/news/ce-marking-commercial...
End
Email:***@abingdonhealth.com Email Verified
Tags:COVID Antibody test
Industry:Medical
Location:York - Yorkshire - England
Subject:Products
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Abingdon Health PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share